12,459 Shares in DaVita Inc. (NYSE:DVA) Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,459 shares of the company’s stock, valued at approximately $2,042,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advisors Asset Management Inc. boosted its holdings in DaVita by 28.9% in the 1st quarter. Advisors Asset Management Inc. now owns 9,398 shares of the company’s stock worth $1,297,000 after acquiring an additional 2,108 shares during the period. BOKF NA boosted its stake in shares of DaVita by 286,550.0% in the first quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after purchasing an additional 5,731 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in DaVita by 0.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,286 shares of the company’s stock valued at $11,775,000 after purchasing an additional 533 shares in the last quarter. Caxton Associates LP purchased a new stake in DaVita during the 1st quarter worth $233,000. Finally, B. Riley Wealth Advisors Inc. boosted its position in DaVita by 9.9% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 2,308 shares of the company’s stock valued at $319,000 after buying an additional 207 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial upped their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Finally, Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, DaVita presently has an average rating of “Hold” and a consensus target price of $161.80.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the sale, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.00% of the company’s stock.

DaVita Stock Performance

DaVita stock opened at $166.99 on Tuesday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 12 month low of $98.26 and a 12 month high of $169.12. The company has a fifty day moving average price of $158.34 and a two-hundred day moving average price of $148.65. The company has a market cap of $13.69 billion, a PE ratio of 18.01, a P/E/G ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the company earned $2.85 EPS. DaVita’s quarterly revenue was up 4.6% on a year-over-year basis. Research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.